OSTERIX Biomarker for Gastrointestinal Tumor Diagnosis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current diagnostic and therapeutic approaches for gastrointestinal tumors lack effective markers for early, specific, and differential diagnosis, which hampers their prognosis and treatment.

Innovation Solution

OSTERIX is identified as a marker for gastrointestinal stem cells and tumors, with its expression being elevated in human gastrointestinal tumors, enabling its use for diagnosis, prognosis, and targeted treatment by assessing biological samples for OSTERIX levels and administering appropriate anticancer agents.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional markers (CEA, CA19-9, K-ras antibody) are used for gastrointestinal tumor diagnosis, then some diagnostic capability is achieved, but the diagnosis lacks early detection sensitivity, specificity, and differential diagnostic accuracy

Engineering Contradiction:

Improvediagnostic accuracyVSAvoidearly detection capability

Core Design Contradiction:

Measurement precisionVSReliability

Solution Approach 1:

The patent identifies and utilizes OSTERIX protein expression levels as a new diagnostic parameter. By measuring OSTERIX expression in biological samples, the patent achieves improved diagnostic accuracy and early detection capability compared to conventional markers. The parameter change from traditional markers to OSTERIX expression levels resolves the contradiction between measurement precision and reliability in gastrointestinal tumor diagnosis.

Inventive Principle:

Principle #35Parameter changes

2Measurement precision

If OSTERIX marker is used for gastrointestinal tumor diagnosis, then diagnostic accuracy and early detection are improved, but the complexity of the diagnostic system increases

Engineering Contradiction:

Improvediagnostic accuracyVSAvoiddiagnostic system complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent employs immunohistochemical staining and immunofluorescence techniques to detect OSTERIX protein expression. These methods replace complex molecular biology assays with more straightforward antibody-based detection systems. The use of commercially available antibodies and standard histological procedures minimizes the increase in system complexity while maintaining high diagnostic accuracy.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Adaptability or versatility

If OSTERIX expression is measured in biological samples, then targeted therapy selection is improved, but the cost and time of treatment assessment increases

Engineering Contradiction:

Improvetargeted therapy selectionVSAvoidtreatment assessment time

Core Design Contradiction:

Adaptability or versatilityVSLoss of time

Solution Approach 1:

The patent performs OSTERIX expression assessment on archived tissue samples and pre-treatment biopsies, allowing therapy selection to be determined before initiating treatment. This preliminary assessment of OSTERIX levels enables clinicians to select appropriate targeted therapies in advance, avoiding delays during treatment initiation while maintaining adaptability to individual patient needs.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS11442065B2Marker for gastrointestinal tumors

Publication Date: 2022.09.13 RHODE ISLAND HOSPITAL

AI summary

The invention provides that OSTERIX (a.k.a. SP7) is a marker for gastrointestinal stem cells and that OSTERIX is expressed widely and at elevated levels in human gastrointestinal tumors.